Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
GW Pharmaceuticals
GW Pharmaceuticals
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Finance
GW Pharmaceuticals reports Epidiolex sales of $296 million in first year
The British biopharmaceutical company has released Q4 and 2019 financial year results
Regulatory
GW Pharmaceuticals gains product recognition by NHS England
Epidyolex (cannabidiol) oral solution and Sativex (nabiximols) have been recommended for use by the UK’s National Institute for Health and Care Excellence
Manufacturing
Momentum in the US cannabidiol market gains retailers' attention
Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
Regulatory
First prescription CBD from GW Pharma has restriction lowered
The US Drug Enforcement Administration’s decision to move Epidiolex to Schedule V was based on non-clinical and clinical data that evaluated the medicine’s potential for abuse
Regulatory
First plant-derived cannabinoid prescription gains FDA approval
GW Pharmaceuticals has announced FDA approval of EPIDIOLEX (cannabidiol) oral solution, a medication prescribed for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome
GW Pharmaceuticals receives orphan drug designation for cannabidiol
The European Medicines Agency granted the designation based on findings from the physician-led cannabidiol expanded access programme
Research & Development
GW Pharmaceuticals announces appointments to Board of Directors
Subscribe now